Histogenics Corp., a regenerative medicine company based in Waltham, said Monday that it has appointed Peter Greenleaf to be its new chief executive.
Greenleaf most recently served as President of MedImmune, the worldwide biologics arm of drug giant AstraZeneca. He also served as the president of MedImmune Ventures, overseeing more than $300 million in investments in early stage portfolio companies.
Greenleaf succeeds Patrick O’Donnell.
Histogenics looks to combine cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. Histogenics’ key product initiatives are focused on providing treatment options for patients suffering from articular cartilage derived pain and immobility.
In an e-mail statement, Histogenics explained why it decided to appoint Greenleaf.
“Histogenics is now a late-stage development company that is rapidly approaching commercialization,” the statement said. “This new set of needs and challenges warranted new leadership and expertise.”
Histogenics was founded in 2001 and has raised $49 million in venture-capital funding.